Singapore markets open in 2 hours 43 minutes

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8300+0.0296 (+3.70%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 34.81M
Enterprise value -19.15M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)72.59
Price/book (mrq)2.11
Enterprise value/revenue -39.98
Enterprise value/EBITDA 0.39

Trading information

Stock price history

Beta (5Y monthly) 1.75
52-week change 3-63.30%
S&P500 52-week change 3-13.20%
52-week high 32.4100
52-week low 30.3500
50-day moving average 30.6090
200-day moving average 30.7886

Share statistics

Avg vol (3-month) 3231.22k
Avg vol (10-day) 3257.27k
Shares outstanding 543.49M
Implied shares outstanding 6N/A
Float 827.75M
% held by insiders 15.43%
% held by institutions 150.77%
Shares short (14 Nov 2022) 4278.08k
Short ratio (14 Nov 2022) 40.96
Short % of float (14 Nov 2022) 40.84%
Short % of shares outstanding (14 Nov 2022) 40.64%
Shares short (prior month 13 Oct 2022) 4147.47k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-3,313.68%

Management effectiveness

Return on assets (ttm)-69.19%
Return on equity (ttm)-130.67%

Income statement

Revenue (ttm)1.55M
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-29.75M
EBITDA -51.25M
Net income avi to common (ttm)-47.64M
Diluted EPS (ttm)-1.2350
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)20.41M
Total cash per share (mrq)0.47
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.54
Book value per share (mrq)0.38

Cash flow statement

Operating cash flow (ttm)-42.2M
Levered free cash flow (ttm)-23.7M